Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Breast Neoplasms 6Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Recurrence 1Neoplasms 1Carcinosarcoma 1Carcinoma, Squamous Cell 1Carcinoma 1Brenner Tumor 1Anus Neoplasms 1

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Brenner Tumor × Paclitaxel × Clear all
NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,873 enrolled 17 charts 1 FDA
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡